Incannex (IXHL) Healthcare announces that it has achieved database lock for the RePOSA Phase 2 clinical trial of IHL-42X, its lead drug candidate for obstructive sleep apnoea, OSA, on schedule as of 16 June 2025. This marks a major milestone in the development of IHL-42X, confirming the completion of clinical data collection and enabling final statistical analysis to begin. The Company is on track to deliver top-line results in July 2025, reinforcing confidence in the program’s momentum and execution.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IXHL:
- Incannex Healthcare Announces Psychedelic Therapies Joint Venture
- Incannex forms joint venture with Mind Medicine Australia
- Incannex Healthcare Transfers Listing to Nasdaq Capital Market
- Incannex Healthcare Cancels Series A Warrants
- Incannex cancels all outstanding Series A warrants following ATM execution
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue